WordNet

a complex consisting of an organic base in association with hydrogen chloride

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/03/23 20:20:12」(JST)

wiki en

Naratriptan (trade names include Amerge and Naramig) is a triptan drug marketed by GlaxoSmithKline and is used for the treatment of migraine headaches. Naratriptan is available in 2.5 mg tablets. It is a selective 5-HT₁ receptor subtype agonist.

Indication

Naratriptan is used for the treatment of the acute migraine attacks and the symptoms of migraine, including severe, throbbing headaches that sometimes are accompanied by nausea and sensitivity to sound or light.^[1]

Mechanism of action

The causes of migraine are not clearly understood; however, the efficacy of naratriptans and other triptans is believed to be due to their activity as 5HT (serotonin) agonists.

Efficacy

A meta-analysis of 53 clinical trials has shown that all triptans are effective for treating migraine at marketed doses and that naratriptan, although less effective than sumatriptan and rizatriptan was more effective than placebo in reducing migraine symptoms at two hours^[2] and efficacy was demonstrated in almost two thirds of subjects after four hours of treatment.^[3]

Side effects

Side effects include: dizziness, drowsiness, tingling of the hands or feet, nausea, dry mouth and unsteadiness. If these effects persist or worsen, notify your doctor promptly. Side-effects which are unlikely and which should be promptly reported include: chest pain/pressure, throat pain/pressure, unusually fast/slow/irregular pulse, one-sided muscle weakness, vision problems, cold/bluish hands or feet, stomach pain, bloody diarrhea, mental/mood changes, and fainting. In the unlikely event you have a serious allergic reaction to this drug, seek immediate medical attention. Symptoms of a serious allergic reaction include: rash, itching, swelling, severe dizziness, trouble breathing (swelling of the throat).

The use of naratriptan with MAOIs and serotonergic drugs may result in the life threatening serotonin syndrome. Make sure your doctor/pharmacist is aware of all your current medications (including as needed medications) before taking this drug. ^[4]

Exclusivity

In the United States, the Food and Drug Administration (FDA) approved naratriptan on February 11, 1998.^[5] It was covered by U.S. Patent no. 4997841; the FDA lists the patent as expiring on July 7, 2010.^[5]^[6]

In July 2010, in the wake of the patent expiration, several drug manufacturers, including Roxane Labs,^[7] Sandoz^[8] and Teva Pharmaceuticals,^[9] announced that they were launching generic Naratriptan medications.

The drug continued to be covered by European patent 0303507 in Germany, Spain, France and the United Kingdom through March 10, 2012,^[10] and by Australian patent 611469 in Australia through June 17, 2013.^[10] It had previously been covered by Canadian patent 1210968; but both Sandoz and Novopharm have offered generic equivalents in Canada since that patent's expiration December 1, 2009.^[10]

Synthesis

Naratriptan synthesis: U.S. Patent 4,997,841

References

^ Medline Plus Drug Information for Naratriptan Accessed 6 August 2009
^ Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002 Oct;22(8):633-58.
^ Efficacy of naratriptan tablets in the acute treatment of migraine: A dose-ranging study. Clin Ther 2000 Aug;22(8):970-80.
^ (( cite web | url = http://www.drugs.com/cdi/naratriptan.html ))
^ ^a ^b FDA AccessData entry for Naratriptan Hydrochloride, accessed September 8, 2008
^ U.S. Patent no. 4997841, Alexander W. Oxford, et al., Indole Derivatives, March 5, 1991
^ DeArment, Alaric (2010-07-09). "Roxane launches generic Amerge, Arimidex". Drug Store News. Retrieved 2010-07-23.
^ DeArment, Alaric (2010-07-12). "Sandoz launches generic Amerge". Drug Store News. Retrieved 2010-07-23.
^ DeArment, Alaric (2010-07-14). "Teva launches generic Amerge". Drug Store News. Retrieved 2010-07-23.
^ ^a ^b ^c Oh, Dae (June 2010). "Drug In Focus: Naratriptan". GenericsWeb. Retrieved 2010-12-15.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 成人における片頭痛の急性期治療 acute treatment of migraine in adults
2. 群発頭痛：治療および予後 cluster headache treatment and prognosis
3. 性行為に伴う一次性頭痛 primary headache associated with sexual activity
4. エストロゲン関連片頭痛 estrogen associated migraine
5. 妊娠中および出産後の女性における頭痛 headache in pregnant and postpartum women

English Journal

Quantitative analysis of eletriptan in human plasma by HPLC-MS/MS and its application to pharmacokinetic study.

Ponnuru VS, Challa BR, Nadendla R.SourceChalapathi Institute of Pharmaceutical Sciences, Lam, Guntur, Andhra Pradesh, 522034, India.
Analytical and bioanalytical chemistry.Anal Bioanal Chem.2011 Nov;401(8):2539-48. Epub 2011 Sep 3.
Authors developed a simple, sensitive, selective, rapid, rugged, and reproducible liquid chromatography-tandem mass spectrometry method for the quantification of eletriptan (EP) in human plasma using naratriptan (NP) as an internal standard (IS). Chromatographic separation was performed on Ascentis
PMID 21892641

Trigeminocervical complex responses after lesioning dopaminergic A11 nucleus are modified by dopamine and serotonin mechanisms.

Charbit AR, Akerman S, Goadsby PJ.SourceHeadache Group - Department of Neurology, University of California San Francisco, San Francisco, CA 94115, USA.
Pain.Pain.2011 Oct;152(10):2365-76. Epub 2011 Aug 24.
Both serotonergic and dopaminergic receptor modulation can alter trigeminal nociceptive processing, and descending A11 dopaminergic projections can affect trigeminal nociceptive transmission. Here we aimed to test the interaction between dopamine D(2) and serotonin 5-HT(1B/1D) receptors and their in
PMID 21868165

Related Pictures

★リンクテーブル★

リンク元	「ナラトリプタン」「塩酸ナラトリプタン」「ナラトリプタン塩酸塩」
関連記事	「naratriptan」「hydrochloride」

「ナラトリプタン」

Naratriptan
Systematic (IUPAC) name
	N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide
Clinical data
Trade names	Amerge
AHFS/Drugs.com	monograph
MedlinePlus	a601083
Pregnancy; category	AU: B3; US: C;
Legal status	℞ Prescription only;
Routes of; administration	Oral
Pharmacokinetic data
Bioavailability	74%
Metabolism	Hepatic
Half-life	5-8 hours
Excretion	Renal
Identifiers
CAS Registry Number	121679-13-8
ATC code	N02CC02
PubChem	CID 4440
IUPHAR ligand	45
DrugBank	DB00952
ChemSpider	4287
UNII	QX3KXL1ZA2
KEGG	D08255
ChEBI	CHEBI:7478
ChEMBL	CHEMBL1278
Chemical data
Formula	C17H25N3O2S
Molecular mass	335.465 g/mol
	SMILES O=S(=O)(NC)CCc3ccc1c(c(cn1)C2CCN(C)CC2)c3;
	InChI InChI=1S/C17H25N3O2S/c1-18-23(21,22)10-7-13-3-4-17-15(11-13)16(12-19-17)14-5-8-20(2)9-6-14/h3-4,11-12,14,18-19H,5-10H2,1-2H3 ; Key:AMKVXSZCKVJAGH-UHFFFAOYSA-N ;
(what is this?) (verify)